Usana Health Sciences (USNA) Cash & Equivalents (2010 - 2026)

Usana Health Sciences (USNA) has reported Cash & Equivalents for 17 consecutive years, with $162.8 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Cash & Equivalents fell 9.39% year-over-year to $162.8 million; the TTM figure through Apr 2026 stood at $162.8 million (down 9.39% YoY), while the FY2026 annual figure was $158.4 million, down 12.87% from the prior year.
• Cash & Equivalents climbed to $162.8 million in Q2 2026 per USNA's latest filing, from $158.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $364.9 million in Q3 2024 and bottomed at $145.3 million in Q3 2025.
• Historically, Cash & Equivalents has averaged $249.0 million across 5 years, with a median of $243.4 million in 2022.
• Annual changes were most pronounced in 2023 — Cash & Equivalents soared 30.3% — and 2025, when it slumped 60.17%.
• Usana Health Sciences' Cash & Equivalents stood at $288.4 million in 2022, then advanced by 14.56% to $330.4 million in 2023, then slumped by 44.99% to $181.8 million in 2024, then declined by 20.04% to $145.3 million in 2025, then grew by 11.97% to $162.8 million in 2026.
• Business Quant data shows USNA's Cash & Equivalents at $162.8 million in Q2 2026, $158.4 million in Q1 2026, and $145.3 million in Q3 2025.